Ryan P Williams1,2, Brenda Banwell1,2, Robert A Berg3, Dennis J Dlugos1,2, Maureen Donnelly4, Rebecca Ichord1,2, Sudha Kilaru Kessler1,2, Jane Lavelle1, Shavonne L Massey1,2, Jennifer Hewlett5, Allison Parker1, Alexis A Topjian4, Nicholas S Abend1,2,4. 1. Department of Pediatrics, The Children's Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A. 2. Department of Neurology, The Children's Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A. 3. Department of Critical Care Medicine, The Children's Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A. 4. Neurodiagnostics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. 5. Department of Pharmacy Services, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A.
Abstract
OBJECTIVES: We aimed to determine whether implementation of a structured multidisciplinary electroencephalography (EEG) monitoring pathway improved the timeliness of administration of antiseizure medication in response to electrographic seizures in encephalopathic critically ill children. METHODS: A multidisciplinary team developed a pathway to standardize EEG monitoring and seizure management in encephalopathic critically ill children, aiming to decrease the time from electrographic seizure onset to antiseizure medication administration. Data were collected to inform the team of improvement opportunities, which were then provided by an institutional pathway, staff education, and streamlined communication. Measurements were obtained before and after pathway implementation to assess for improvement. RESULTS: We collected data on 41 patients before and 21 after pathway implementation. There were no differences between the baseline and pathway groups in demographic characteristics, acute encephalopathy etiologies, or antiseizure medications utilized. The median duration [interquartile range, IQR] from seizure onset to antiseizure medication administration was shorter for patients treated with the pathway (64 min [50, 101]) compared to patients treated prior to pathway implementation (139 min [71, 189]; p = 0.0006). The median [IQR] interval from seizure onset to antiseizure medication order was shorter for the pathway group (31 min [20, 49]) than the baseline group (71 min [33, 131]; p = 0.003). The median [IQR] interval from antiseizure medication order to administration was shorter for the pathway group (30 min [19, 40]) than the baseline group (40 min [17, 68]) (p = 0.047). Seizure termination was more likely to occur following initial antiseizure medication administration in the pathway than baseline group (67% vs. 27%, p = 0.002). SIGNIFICANCE: Implementation of the pathway resulted in a significant reduction in the duration between electrographic seizure onset and antiseizure medication administration, and a significant increase in the rate of electrographic seizure termination following an initial antiseizure medication. Further study is needed to determine whether these changes are associated with improved outcomes. Wiley Periodicals, Inc.
OBJECTIVES: We aimed to determine whether implementation of a structured multidisciplinary electroencephalography (EEG) monitoring pathway improved the timeliness of administration of antiseizure medication in response to electrographic seizures in encephalopathic critically illchildren. METHODS: A multidisciplinary team developed a pathway to standardize EEG monitoring and seizure management in encephalopathic critically illchildren, aiming to decrease the time from electrographic seizure onset to antiseizure medication administration. Data were collected to inform the team of improvement opportunities, which were then provided by an institutional pathway, staff education, and streamlined communication. Measurements were obtained before and after pathway implementation to assess for improvement. RESULTS: We collected data on 41 patients before and 21 after pathway implementation. There were no differences between the baseline and pathway groups in demographic characteristics, acute encephalopathy etiologies, or antiseizure medications utilized. The median duration [interquartile range, IQR] from seizure onset to antiseizure medication administration was shorter for patients treated with the pathway (64 min [50, 101]) compared to patients treated prior to pathway implementation (139 min [71, 189]; p = 0.0006). The median [IQR] interval from seizure onset to antiseizure medication order was shorter for the pathway group (31 min [20, 49]) than the baseline group (71 min [33, 131]; p = 0.003). The median [IQR] interval from antiseizure medication order to administration was shorter for the pathway group (30 min [19, 40]) than the baseline group (40 min [17, 68]) (p = 0.047). Seizure termination was more likely to occur following initial antiseizure medication administration in the pathway than baseline group (67% vs. 27%, p = 0.002). SIGNIFICANCE: Implementation of the pathway resulted in a significant reduction in the duration between electrographic seizure onset and antiseizure medication administration, and a significant increase in the rate of electrographic seizure termination following an initial antiseizure medication. Further study is needed to determine whether these changes are associated with improved outcomes. Wiley Periodicals, Inc.
Authors: Nicholas S Abend; Katherine L Wagenman; Taylor P Blake; Maria T Schultheis; Jerilynn Radcliffe; Robert A Berg; Alexis A Topjian; Dennis J Dlugos Journal: Epilepsy Behav Date: 2015-04-20 Impact factor: 2.937
Authors: Susan T Herman; Nicholas S Abend; Thomas P Bleck; Kevin E Chapman; Frank W Drislane; Ronald G Emerson; Elizabeth E Gerard; Cecil D Hahn; Aatif M Husain; Peter W Kaplan; Suzette M LaRoche; Marc R Nuwer; Mark Quigg; James J Riviello; Sarah E Schmitt; Liberty A Simmons; Tammy N Tsuchida; Lawrence J Hirsch Journal: J Clin Neurophysiol Date: 2015-04 Impact factor: 2.177
Authors: Iván Sánchez Fernández; Nicholas S Abend; Satish Agadi; Sookee An; Ravindra Arya; James Nicholas Brenton; Jessica L Carpenter; Kevin E Chapman; William D Gaillard; Tracy A Glauser; Howard P Goodkin; Kush Kapur; Mohamad A Mikati; Katrina Peariso; Margie Ream; James Riviello; Robert C Tasker; Tobias Loddenkemper Journal: Neurology Date: 2015-05-06 Impact factor: 9.910
Authors: Stacey K H Tay; Lawrence J Hirsch; Linda Leary; Nathalie Jette; John Wittman; Cigdem I Akman Journal: Epilepsia Date: 2006-09 Impact factor: 5.864
Authors: France W Fung; Marin Jacobwitz; Lisa Vala; Darshana Parikh; Maureen Donnelly; Rui Xiao; Alexis A Topjian; Nicholas S Abend Journal: Epilepsia Date: 2019-09-20 Impact factor: 5.864
Authors: Cynthia Sharpe; Gail E Reiner; Suzanne L Davis; Mark Nespeca; Jeffrey J Gold; Maynard Rasmussen; Rachel Kuperman; Mary Jo Harbert; David Michelson; Priscilla Joe; Sonya Wang; Neggy Rismanchi; Ngoc Minh Le; Andrew Mower; Jae Kim; Malcolm R Battin; Brian Lane; Jose Honold; Ellen Knodel; Kathy Arnell; Renee Bridge; Lilly Lee; Karin Ernstrom; Rema Raman; Richard H Haas Journal: Pediatrics Date: 2020-05-08 Impact factor: 7.124
Authors: Jian Hu; France W Fung; Marin Jacobwitz; Darshana S Parikh; Lisa Vala; Maureen Donnelly; Alexis A Topjian; Nicholas S Abend; Rui Xiao Journal: Seizure Date: 2021-03-04 Impact factor: 3.184
Authors: France W Fung; Zi Wang; Darshana S Parikh; Marin Jacobwitz; Lisa Vala; Maureen Donnelly; Alexis A Topjian; Rui Xiao; Nicholas S Abend Journal: Neurology Date: 2021-04-23 Impact factor: 11.800
Authors: Iván Sánchez Fernández; Nicholas S Abend; Marta Amengual-Gual; Anne Anderson; Ravindra Arya; Cristina Barcia Aguilar; James Nicholas Brenton; Jessica L Carpenter; Kevin E Chapman; Justice Clark; Raquel Farias-Moeller; William D Gaillard; Marina Gaínza-Lein; Tracy Glauser; Joshua Goldstein; Howard P Goodkin; Réjean M Guerriero; Yi-Chen Lai; Tiffani McDonough; Mohamad A Mikati; Lindsey A Morgan; Edward Novotny; Eric Payne; Katrina Peariso; Juan Piantino; Adam Ostendorf; Tristan T Sands; Kumar Sannagowdara; Robert C Tasker; Dimtry Tchapyjnikov; Alexis A Topjian; Alejandra Vasquez; Mark S Wainwright; Angus Wilfong; Kowryn Williams; Tobias Loddenkemper Journal: Neurology Date: 2020-07-01 Impact factor: 9.910
Authors: Céline Thibault; Shavonne L Massey; Nicholas S Abend; Maryam Y Naim; Alexandra Zoraian; Athena F Zuppa Journal: J Clin Pharmacol Date: 2020-09-22 Impact factor: 3.126
Authors: Joel R Martin; Paolo G Gabriel; Jeffrey J Gold; Richard Haas; Suzanne L Davis; David D Gonda; Cynthia Sharpe; Scott B Wilson; Nicolas C Nierenberg; Mark L Scheuer; Sonya G Wang Journal: J Clin Neurophysiol Date: 2022-03-01 Impact factor: 2.590